Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Aurinia reported Q1 revenue of $77.7 million, up 24% year-over-year, driven by a 23% increase in LUPKYNIS net product sales to $73.6 million. Diluted EPS rose 56% to $0.25, supported by a 90% increase in operating income to $41.4 million, while the company reaffirmed full-year revenue guidance of $315 million to $325 million.
Key figures
- Eps
- 0.25
- Revenue
- 77700000
- Guidance
- 2026 total revenue $315M-$325M, up 11-15% compared to 2025
- Revenue Yoy
- 24%
- Net income
- 34355000
- Operating income
- 41422000
- Net product sales
- 73600000
- Shares repurchased
- 2500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.